Literature DB >> 24471567

Association between sex steroid levels and bone microarchitecture in men: the STRAMBO study.

Thomas Argoud1, Stéphanie Boutroy, Bruno Claustrat, Roland Chapurlat, Pawel Szulc.   

Abstract

CONTEXT: Data on the association between bone microarchitecture assessed by high-resolution peripheral quantitative computed tomography (HR-pQCT) and sex steroids in men are scarce.
OBJECTIVE: Our aim was to determine the association between serum sex steroids and bone microarchitecture assessed by HR-pQCT in men.
DESIGN: This is a cross-sectional analysis in the Structure of the Aging Men's Bones cohort.
SETTING: The cohort was recruited from the general population. PARTICIPANTS: We examined 1169 male volunteers aged 20-87 years. No specific exclusion criteria were used.
INTERVENTIONS: We collected blood samples and performed HR-pQCT at the distal radius and distal tibia. MAIN OUTCOME MEASURES: We tested the hypothesis that low sex steroid levels are associated with poor bone microarchitecture in men.
RESULTS: Men aged younger than 65 years with bioavailable 17β-estradiol (bio-17β-E2) levels of14.4 pmol/L or less had higher cross-sectional and trabecular areas vs men with bio-17β-E2 greater than 14.4 pmol/L. In men aged 65 years or older, the higher the apparent free T concentration (AFTC), the higher was the distal tibia cortical density (P < .05). Cortical density and thickness as well as total and trabecular density increased with higher bio-17β-E2 levels. Similar results were found after adjustment for limb length and body height. Men with low AFTC and low bio-17β-E2 levels had lower cortical density and thickness at both skeletal sites compared with the reference group. In men with AFTC less than 272 pmol/L, those with low bio-17β-E2 less than 25 pmol/L had lower cortical density and thickness at both skeletal sites vs men having higher bio-17β-E2 levels.
CONCLUSION: In men aged 65 years and older, low bio-17β-E2 levels were associated with poor cortical bone status and, to smaller extent, lower trabecular density.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24471567     DOI: 10.1210/jc.2013-3233

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

Review 1.  An update on enzalutamide in the treatment of prostate cancer.

Authors:  Axel S Merseburger; Gabriel P Haas; Christoph-A von Klot
Journal:  Ther Adv Urol       Date:  2015-02

2.  Battle of the sex steroids in the male skeleton: and the winner is....

Authors:  Thomas J Weber
Journal:  J Clin Invest       Date:  2016-02-22       Impact factor: 14.808

3.  Estrogens, the be-all and end-all of male hypogonadal bone loss?

Authors:  M R Laurent; E Gielen; D Vanderschueren
Journal:  Osteoporos Int       Date:  2014-11-07       Impact factor: 4.507

Review 4.  Estrogens and Androgens in Skeletal Physiology and Pathophysiology.

Authors:  Maria Almeida; Michaël R Laurent; Vanessa Dubois; Frank Claessens; Charles A O'Brien; Roger Bouillon; Dirk Vanderschueren; Stavros C Manolagas
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

5.  Risk Factors for the Incident Decline of Physical Performance in Older Men: The Prospective Strambo Study.

Authors:  Philippe Paul Wagner; Dominique Foesser; Roland Chapurlat; Pawel Szulc
Journal:  Calcif Tissue Int       Date:  2021-10-30       Impact factor: 4.333

6.  Body composition and circulating estradiol are the main bone density predictors in healthy young and middle-aged men.

Authors:  S C Bilha; D Branisteanu; C Buzduga; D Constantinescu; P Cianga; E Anisie; A Covic; M C Ungureanu
Journal:  J Endocrinol Invest       Date:  2018-01-16       Impact factor: 4.256

Review 7.  Sex steroid actions in male bone.

Authors:  Dirk Vanderschueren; Michaël R Laurent; Frank Claessens; Evelien Gielen; Marie K Lagerquist; Liesbeth Vandenput; Anna E Börjesson; Claes Ohlsson
Journal:  Endocr Rev       Date:  2014-09-09       Impact factor: 19.871

8.  Effects of aromatase inhibition vs. testosterone in older men with low testosterone: randomized-controlled trial.

Authors:  J P Dias; D Melvin; E M Simonsick; O Carlson; M D Shardell; L Ferrucci; C W Chia; S Basaria; J M Egan
Journal:  Andrology       Date:  2015-11-20       Impact factor: 3.842

Review 9.  Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis.

Authors:  Vittorio Locatelli; Vittorio E Bianchi
Journal:  Int J Endocrinol       Date:  2014-07-23       Impact factor: 3.257

10.  High risk of fall, poor physical function, and low grip strength in men with fracture-the STRAMBO study.

Authors:  Pawel Szulc; Clément Feyt; Roland Chapurlat
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-11-19       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.